Pam was Director of Chemistry at Cantab Anti-infectives, where the team delivered the cyclic peptide SPR206 with activity against multi-drug resistant Gram-negative bacterial pathogens, and which is now being progressed through the clinic by Spero Therapeutics. Since 2017, Pam has operated as an independent consultant in antibacterial drug discovery and medicinal chemistry with clients in the UK, US, and Australia.


Pam holds a degree in Chemistry from Imperial College and is a Fellow of the Royal Society of Chemistry. Pam has over 40 publications in patents and peer-reviewed journals on the design and synthesis of antibacterial agents in a variety of classes.


Pam has over 35 years experience in anti-infective drug discovery, the majority gained at GSK where she held team leadership roles in medicinal chemistry, developing small molecule therapeutic agents through hit-to-lead and lead optimisation projects towards a variety of bacterial targets.